

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Offic

Address:

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/461,0	61 12/15	199 MCCRAE	K	6056-260
		\neg		EXAMINER
		HM22/0913	-	
SEIDEL G	ONDA LOVORI	NA & MONACO PC	BORINSON H	
SUITE 18	00		ART UNIT	PAPER NUMBER
TWO PENN CENTER PLAZA				
PHILADEL	PHIA PA 19:	.02	165:	₄ /3
			DATE MAILED:	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

09/13/01

Application No. A

Applicatit(s)

McCrae

Office Action Summary

Examiner

Hope Robinson

Art Unit 1653



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on *Jul 13, 2001* 2a) This action is **FINAL**. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4) X Claim(s) 1-8 and 12-45 4a) Of the above, claim(s) ______ is/are withdrawn from consideration. 5) U Claim(s) 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. are subject to restriction and/or election requirement. 8) X Claims 1-8 and 12-45 **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are objected to by the Examiner. 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) ☐ All b) ☐ Some* c) ☐ None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 18) Interview Summary (PTO-413) Paper No(s). 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 20) Other: 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

Serial Number 09/461,061 Art Unit 1653

10

20

25

Restriction/Election

- Restriction to one of the following inventions is required under
 35 U.S.C. 121:
 - I. Claims 1-8 and 12-24 are drawn to a pharmaceutical composition, classified in class 514, subclass 12+.
 - II. Claims 25 and 27-45, are drawn to a method of inhibiting endothelial cell proliferation, classified in class 435, subclass 70.1
 - III. Claim 26 is drawn to a method of inducing endothelial cell apoptosis, classified in class 435, subclass 7.21.
- The inventions are distinct, each from the other because of the following reasons:

Inventions I-III are related as the composition of Invention I is used in the methods of Invention II and III. However, the inventions are patentably distinct because the methods of Invention II and III are alternative methods of using the composition as Invention I encompasses a method of using the composition with a different end point.

Inventions II and III are patentably distinct because the two methods have different endpoints which are opposed.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Serial Number 09/461,061 Art Unit 1653

... · · · -

5

10

15

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Hope A. Robinson whose telephone number is (703)308-6231. The Examiner can normally be reached on Monday and Wednesday - Friday from 9:00 A.M. to 5:30 P.M. (EST).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor Christopher S.F. Low, can be reached at (703)308-2923.

Any inquiries of a general nature relating to this application should be directed to the Group Receptionist whose telephone number is (703)308-0196.

Papers related to this application may be submitted by facsimile transmission. The official fax phone number for Technology Center 1600 is (703) 308-4242. Please affix the Examiner's name on a cover sheet attached to your communication should you choose to fax your response. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989).

25

20

Chris hyphr SSh

Hope A. Robinson, MS

Patent Examiner

CHRISTOPHER S. F. LOW
PERVISORY PATENT EXAMINER
FECHNOLOGY CENTER 1600